BVT Bonus Zert AMD 28.03.2025/ DE000VM96FC9 /
| 5/14/2024 10:13:21 AM | Chg.-0.900 | Bid11:20:47 AM | Ask11:20:47 AM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 141.030EUR | -0.63% | 141.100 Bid Size: 1,900 |
141.250 Ask Size: 1,900 |
Advanced Micro Devic... | - USD | 3/28/2025 | Call |
GlobeNewswire
3:50 AM
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/13
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
5/13
AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire
5/9
Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
5/9
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire
5/8
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire
5/8
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire
5/8
AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire
5/8
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire
5/8
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire
5/7
Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire
5/6
Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire
5/6
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire
5/6
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire
5/6
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire
5/3
YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...
